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Abstract
PURPOSE: PD173074, a small molecule inhibitor of
VEGF-RII and FGF-RI, targets neoangiogenesis and
mitogenesis. This study aimed to analyze a single-
compound-driven inhibition of FGF and VEGF recep-
tors in pancreatic cancer. EXPERIMENTAL DESIGN:
RT-PCR and Western blots were performed to quantify
protein expression and phosphorylation. Anchorage
dependent and independent growth assays were used
to study cell growth. With flow cytometry, cell cycle
analysis and apoptosis were studied. In vivo HPAF-II
and MIA PaCa-2 cells were xenografted. Animals were
treated daily for 10 weeks. Immunohistochemistry was
used to quantify microvessel density and apoptosis.
RESULTS: Highest levels of FGF-RI were detectable
in MIA PaCa-2 cells, lowest in HPAF-II cells. PD173074
inhibited cell growth most prominently in cells ex-
pressing high levels of FGF-RI. Cell cycle progression
was inhibited by blocking transition in the G0/G1 phase,
and consequently, apoptosis was increased. In vivo
significant inhibition of orthotopic tumor growth was
achieved by a combination effect of inhibition of mito-
genesis, induction of apoptosis, and reduction of
angiogenesis in PD173074-treated animals. CONCLU-
SIONS: These data highlight VEGF-RII and FGF-RI as
therapeutic targets and suggest a potential role for the
combined use of tyrosine kinase inhibitors in the
management of inoperable pancreatic cancer patients.
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Introduction
Angiogenesis is an essential physiological process during
organ development but is also involved in many patho-
logical circumstances such as diabetic retinopathy, athero-
sclerosis, cancer growth, and metastasis [1,2]. Pancreatic
cancer is the fourth or fifth leading cause of cancer death in
western countries, with nearly 32,000 people diagnosed an-
nually and with almost the same number of patients dying
from this disease in the United States [3]. Overall, the
incidence of pancreatic cancer remains stable in men but,
for unknown reasons, is rising in women [3–5]. Apart from a
few patients suffering from certain types of hereditary pancre-
atitis, little is known about risk factors for this disease [6].
The highly aggressive nature of pancreatic cancer remains
to be elucidated but could be due to differential expression of
growth factors, resulting in high constitutive intrinsic tyrosine
kinase activity, which simultaneously stimulates cell prolifera-
tion and tumor angiogenesis [7–9]. An increasing awareness of
the role of tumor neoangiogenesis in the growth of solid tumors
has led to a consensual opinion that abrogated neoangio-
genesis may cause tumor growth arrest [10].
Numerous studies have indicated that angiogenesis in-
volves different cytokines, such as vascular endothelial growth
factor (VEGF), basic fibroblast growth factor (bFGF), or angio-
poietin 1 [11,12]. As of now, it appears that members of the
FGF—in particular the VEGF—family are the most potent pro-
teins involved in tumor neoangiogenesis and, in the case of
pancreatic cancer, possess an additional mitogenic effect [13].
VEGF and bFGF are overexpressed in pancreatic cancer and
accelerate tumor growth [14,15]. The cellular effects of these
peptides are mediated by specific cell surface receptors with
intrinsic tyrosine kinase activity [16–21]. Disruption of VEGF
signaling with neutralizing antibodies or by dominant-negative
Flk-1 receptor mutants slows tumor growth. In contrast, sup-
pression of VEGF signaling alone had no effect on tumor
growth, suggesting that other angiogenic factors may substi-
tute for VEGF or bFGF [22,23]. This switch might be of par-
ticular interest because FGF-RI activation causes activation
of mitogen-activated protein kinases, which in turn regulate
VEGF gene expression [24–26].
In the present study, we analyzed the preclinical therapeutic
potential of a novel small molecule inhibitor, designated
PD173074, in vitro and in vivo using a clinically relevant ortho-
topic model for pancreatic cancer [27,28]. This small molecule
inhibitor has been shown to be a highly selective tyrosine kinase
inhibitor for both FGF-RI in lower doses (f 25nM) andVEGF-RII
signaling in higher doses (f 100 nM) [27,28] in fibroblasts.
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Because of its antiangiogenic potential in angiogenic tumor
model systems, we used this compound in higher doses to
simultaneously inhibit FGF-RI and VEGF-RII signaling and to
tailor therapy to pancreatic cancer because cancer cells
require higher drug doses for growth suppression. We hy-
pothesized that simultaneous blockade of these receptors
may not only abrogate angiogenic pathways but also bifunc-
tionally downregulate tumor cell proliferation.
Materials and Methods
Cell Culture
Five human pancreatic cancer cell lines (AsPC-1, Capan-1,
HPAF-II, MIA PaCa-2, and PANC-1) were used in vitro,
and MIA PaCa-2 and HPAF-II were also studied in vivo
[29–33]. All cancer cell lines were purchased from the
American Type Culture Collection (Rockville, MD) and cul-
tured in Dulbecco’s modified Eagle’s medium or RPMI 1640
medium supplemented with 10% heat-inactivated fetal bo-
vine serum, penicillin G (100U/ml), and streptomycin (100 mg/
ml). Human umbilical vein endothelial cells (HUVECs) were
cultured in an endothelial cell growth medium containing
an endothelial cell growth supplement (PromoCell GmbH,
Heidelberg, Germany). Normal human dermal fibroblasts
(NHDFs) were purchased from PromoCell GmbH and cul-
tured in fibroblast growth medium supplemented with insu-
lin (5 mg/ml) and bFGF at a final concentration of 1 ng/ml. All
cell culture chemicals were purchased from Life Technology
(Rockville, MD). All other chemicals were obtained from
Sigma Chemicals (St. Louis, MO), unless otherwise indi-
cated. PD173074 was kindly provided by Parke-Davis (Ann
Arbor, MI). The doses of PD173074 tested were 0, 1, 10, and
50 mM, or an equal volume of solvent, which was used as the
solvent of PD173074. The doses used in this study were
chosen because lower doses used for endothelial growth
suppression did not inhibit pancreatic cancer cell growth.
All in vitro growth studies were performed in 35-mm dishes
as a monolayer culture with logarithmically growing cultures.
Cell Number, Viability, and Growth
To determine the cell number, cells were trypsinized and
pelleted by centrifugation for 5 minutes at 1500 rpm, resus-
pended in 10 ml of phosphate-buffered saline (PBS), and
counted with an improved Neugebauer hemocytometer. Cell
viability was assayed by MTT [3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide] colorimetric assay [34]
using a commercially available kit (Boehringer Mannheim,
Mannheim, Germany) according to the manufacturer’s in-
structions. Absorbency readings were performed on a
540-nm multiwell spectrophotometer ELISA Reader (Biotek
Instruments, Burlington, VT).
Cell Proliferation Assay
For [3H]thymidine incorporation, 1  104 to 3  104 cells
were grown for 2 days in complete cell medium and serum-
starved for 24 hours. After serum deprivation, cells were
grown in normal cell type–specific medium, and DNA syn-
thesis was measured by adding 5 mCi of [3H]thymidine (APB,
Uppsala, Sweden) for 6 hours. Cultures were washed with
PBS, fixed with 5% trichloracetic acid (TCA), and lysed in
500 ml of lysis base containing 0.1 N NaOH + 1% sodium
dodecyl sulfate (SDS). Afterward, [3H]thymidine incorpora-
tion was measured by liquid scintillation counting (Beckman,
Fullerton, CA). The assays were performed in triplicate and
repeated at least twice.
Cell Cycle Analysis with Flow Cytometry
Samples were analyzed on a FACScan flow cytometer
(Becton Dickinson Immunocytometry Systems, San Jose,
CA) equipped with a 488-nm argon ion laser. Green fluores-
cein isothiocyanate (FITC) fluorescence was collected with
a 530/30–nm bandpass filter. Orange emission from propi-
dium iodide (PI) was filtered through a 585/42–nm bandpass
filter. Emission of 7-amino-actinomycin D (7-AAD) was col-
lected through a 650-nm longpass filter. Photomultiplier
tube voltage and spectral compensation were initially set
using cells single-stained with either FITC-labeledmonoclonal
antibody, PI, or 7-AAD alone. FITC and 7-AAD fluorescence
data were shown on four-decade log scales. PI fluorescence
was collected using linear amplification, in addition to FL-2
(orange fluorescence) height. FL-2 areas (A) and width (W )
were measured to permit doublet discrimination. A low flow
rate setting (12 ml/min) was used for sample acquisition to
improve the coefficient of variation (%CV) onDNAhistograms.
A minimum of 7500 events was collected on each sample.
Analysis of multivariate data was performed with CELLQuest
software (Becton Dickinson Immunocytometry Systems).
Cell cycle analysis of DNA histograms was performed with
ModFit LTsoftware (Verity Software House, Topsham, ME).
Apoptosis Assays
The amount of apoptotic cells was analyzed with an-
nexin V binding using an Annexin V FLOUS Staining Kit
(BoehringerMannheim). Briefly, cells were washed twice with
PBS and then resuspended in 100 ml of annexin V staining
solution, which consisted of 20 ml of FITC-conjugated an-
nexin V reagent (20 mg/ml), 20 ml of isotonic PI (50 mg/ml), and
1000 ml of 1 M HEPES buffer (all supplied by the manu-
facturer). Cells were incubated in staining solution for 10min-
utes at 25jC. Following this incubation, 500 ml of binding
buffer (supplied by the manufacturer) was added, and cells
were analyzed by flow cytometry. Samples were analyzed
on a FACScan flow cytometer (Becton Dickinson Immuno-
cytometry Systems) equipped with a 15-nW air-cooled
488-nm argon ion laser. Because positive annexin V staining
is seen for apoptotic and necrotic cells, PI was used to differ-
entiate between these two subgroups. Annexin V–positive
and PI-positive cells were considered necrotic cells, where-
as annexin V–positive and PI-negative cells were counted
as apoptotic cells.
Soft Agar Colony-Forming Assay
For anchorage-independent growth assays, a bottom
layer of 1 ml of cell type–specific medium containing 0.7%
agar (DIFCO, Detroit, MI) and 10% fetal bovine serum was
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poured. Then 1  104 cells were added in 1 ml of complete
culture medium, 0.35% agar, and various concentrations of
PD173074. Cells were incubated in cell type–specific culture
conditions; after 10 days, MTT reagent, which is exclusively
metabolized by living cells, was added at a final concentration
of 0.5 mg/ml for vital staining. Colonies with > 20 cells were
counted manually.
Immunoprecipitation and Western Blot Analysis
Cells were lysed in radioimmunoprecipitation assay buffer
(1 PBS, 1% Nonidet P-40, 0.5% sodium deoxycholate, and
0.1% SDS) with a protein inhibitor (10 ml/ml radioimmuno-
precipitation assay buffer of 10 mg/ml phenylmethylsulfonyl
fluoride in isopropanol, 30 ml/ml radioimmunoprecipitation
assay buffer of aprotinin, and 10 ml/ml radioimmuno-
precipitation assay buffer of 100 mmol of sodium orthovana-
date). Samples were incubated on ice for 30 minutes and
centrifuged at 10,000g for 15 minutes. Protein concentra-
tions were determined, and FGF-RI was detected by a
specific antibody recognizing the COOH terminus of each
of these FGF-RI (1:1000; Santa Cruz Biotechnology, Santa
Cruz, CA). Equal amounts of protein were immunoprecipi-
tated with antisera FGF-RI attached to protein A/G plus
agarose beads and separated on 8% polyacrylamide gel.
Immunoblotting analyses were performed by probing with
a monoclonal antiphosphotyrosine (PY99; Santa Cruz Bio-
technology) and with FGF-R as control. The effect of FGF-R
tyrosine kinase inhibition was also examined in the pres-
ence of FGF-1 stimulation (5 ng/ml) for 15 minutes. Similarly,
VEGF-RII was immunoprecipitated with an antireceptor
antibody, followed by immunoblotting with an antiphospho-
tyrosine monoclonal antibody.
Tumor Induction in Athymic Nude Mice
Five-week-old male nude mice (BALB/Ca) were used for
subcutaneous and orthotopic tumor implantations [35,36].
The experimental protocol was approved by the Chancellor’s
Animal Research Committee of the University of California
(Los Angeles, CA) in accordance with national guidelines for
animal care and the use of laboratory animals. The poorly
differentiated human pancreatic cancer cell line MIA PaCa-2
and the more differentiated HPAF-II cell line were used for
xenograft tumor induction. After subcutaneous tumor for-
mation, one small tumor fragment (f 1 mm in diameter)
was removed from the subcutaneous tumor and trans-
planted into the tail of the mouse pancreas. To standardize
experimental conditions in vivo, all 20 animals for each cell
line to be tested were transplanted in the same session
with tumor pieces from the same subcutaneous tumor and
randomly assigned to either the PD173074-treated group
(n = 10) or the sham-treated group (n = 10). After orthotopic
tumor transplantation, the mice were inspected daily. The
growth rate of the tumor was monitored by abdominal palpa-
tion, and tumor volume was determined after the sacrifice
of animals using the formula: tumor volume = 1/2(length 
width  depth). Metastatic tumor spread was determined
macroscopically in all thoracic, abdominal, retroperitoneal,
and pelvic organs, and all suspicious lesions were confirmed
by microscopic analysis. Metastatic spread was quantified
by counting different organs that contained metastatic
lesions. Thus, every point in themetastatic score represented
a different organ of metastatic tumor spread, as previously
described [35]. Ascites volume was measured with a single-
channel adjustable 1000-ml laboratory Eppendorf pipette.
Therapeutic Efficiency of PD173074 in Athymic Nude Mice
One week after orthotopic tumor transplantation, treat-
ment was initiated. PD173074 (25 mg/kg per day) was given
intraperitoneally in a volume of 0.1 ml in PBS, which also
served as control vehicle. Treatment was continued until
sacrifice, which was performed when clinical signs of excess
tumor burden, such as cachexia or ascites with abdominal
distension, became evident or when the tumor has grown
larger than 1.5 cm.
Immunohistochemical Labeling for the Quantitation
of Microvessel Density (MVD)
Tumors were fixed in 10% buffered formalin, embedded in
paraffin, and sectioned (2–4 mm) for hematoxylin–eosin
staining or immunohistochemistry. Apoptosis staining was
performed using the TUNEL method according to the man-
ufacturer’s instructions (Roche Diagnostics, Penzberg, Ger-
many). Labeling of microvessels was performed with rat
anti-mouse CD31 (PharMingen, San Diego, CA), followed
by biotinylated goat anti-rat antibody (Jackson Immuno-
Research Laboratories, West Grove, PA) and streptavidin-
conjugated horseradish peroxidase (DAKO, Carpinteria, CA)
using a protocol that has been previously described in detail
[36]. Quantification of MVD has been described previously
[36–40]. Briefly, MVD was determined using three sections
of each xenograft tumor cut from different tumor regions. On
each slide, three vascular hot spots were selected by scan-
ning a tumor section at low magnification (40). Once the
vascular hot spot has been defined, a higher magnification
was selected to be able to count individual microvessels.
Magnifications on the order of 200 and a field size of
0.25 mm2 were used [37,39,40]. Thus, quantification of
stained vessels was achieved by measuring the highest
microvascular density. All measurements were performed
by a single pathologist blinded to the sample’s identity.
Statistical Analysis
Experiments were repeated at least thrice. Results are
expressed as mean ± SE. Statistical significance was deter-
mined by Student’s t test (P < .05).
Results
FGF-RI Expression in Pancreatic Cancer Cell Lines
It has previously been reported that the angiogenic
system consisting of VEGF and its receptors VEGF-RI and
VEGF-RII is activated in human pancreatic cancer growth
[7,41]. Therefore, we determined the expression and phos-
phorylation of FGF-RI. We measured FGF-RI mRNA by
reverse transcription–polymerase chain reaction (RT-PCR),
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and protein expression was quantified by Western blot anal-
ysis. FGF-RI mRNA expression was detectable in three of
five cell lines (Figure 1A). In Western blot analysis, these
cell lines also exhibited the expression of FGF-RI protein,
whereas cell lines devoid of FGF-RI mRNA did not express
relevant protein levels (Figure 1A). Whether PD173074
inhibits FGF-RI or VEGF-RII phosphorylation in pancreatic
cancer cells was tested in the AsPC-1 cell line. Cell lysates
from PD173074-treated cells were subjected to FGF-RI
immunoprecipitation, followed by blotting with an anti-
phosphotyrosine antibody. In the case of VEGF-RII, immuno-
precipitation was performed with an antiphosphotyrosine
antibody, followed by blotting with VEGF-2 antibody. Although
robust FGF-1–mediated and VEGF-mediated phosphoryla-
tions were evident in the absence of the small molecule
inhibitor PD173074, cells pretreated with PD173074 showed
a dose-dependent inhibition of FGF-RI and VEGF-RII phos-
phorylation (Figure 1B). The functional relevance of this ob-
servation was further studied in cell proliferation assays
measuring DNA synthesis by [3H]thymidine uptake. In this
assay, mitogenic response was detectable on stimulation of
pancreatic cancer cells with recombinant human VEGF and
FGF-1 (Figure 2). The mitogenic response induced by the
addition of either of the two cytokines was blocked by increas-
ing doses of PD173074, which in high doses even suppressed
the basal cell proliferation rate (Figure 2B). The functional
relevance of the VEGF-mediated growth stimulation of pan-
creatic cancer cells has previously been reported [7,8,41].
PD173074 Suppressed Cell Growth
The culture of pancreatic cancer cell lines in the pres-
ence of PD173074 resulted in a dose-dependent and time-
dependent growth suppression. This finding was detectable
in cell counts (Figure 3, B and D) and was confirmed in MTT
assays (Figure 3, B and D), where a strong time-dependent
(Figure 3, A and B) and dose-dependent (Figure 3, C and D)
growth inhibition was detectable. The IC50 dose of pancreatic
cancer cell lines was in the range of 2.5 to 15 mM, depending
on the individual cancer cell line (data not shown). In com-
parison, nontransformed normal human cells are more sus-
ceptible to PD173074 therapy (50-fold to 100-fold) than are
cancer cells. HUVECs and human fibroblast cells showed
a marked reduction in cell viability at PD173074 doses of
0.01 to 0.1 mM, as analyzed by MTTassays (Figure 3E ).
Figure 1. Expression of FGF-RI in pancreatic cancer cell lines. (A) mRNA
was isolated, and RT-PCR was performed. After PCR with specific primers
for FGF-RI, the PCR product was separated on a 1% agarose gel (upper
panel). The corresponding FGF-RI Western blot analysis is shown below
(lower panel). In (B), the effect of PD173074 on FGF-RI and VEGF-RII
signaling is shown. AsPC-1 cells were grown for 24 hours in the presence or
in the absence of PD173074 and were stimulated for 15 minutes with FGF-1
(50 g/ml) in the presence of heparin or stimulated with recombinant human
VEGF (25 ng/ml). Total cell lysates were immunoprecipitated (IP); sub-
sequently, immunoblotting (IB) was performed with the indicated antibodies.
Figure 2. [3H]thymidine incorporation on FGF-1 and VEGF stimulation of various human pancreatic cancer cell lines. (A) Cells (f 5  104) were grown for 3 days
and stimulated with different doses of recombinant human VEGF (1 and 10 ng/ml). In (B), cells were stimulated with recombinant human FGF-1 (0, 1, and 5 ng/ml).
The inhibitory effect of PD173074 was tested by adding PD173074, 60 minutes before the addition of growth factors at two different concentrations (1 and 10 M).
After 14 hours of stimulation, cells were pulse-labeled for 6 hours with [3H]thymidine (0.25 Ci/ml). Values represent the mean ± SE of at least three independent
experiments. *P < .05, compared with untreated cells. #P < .05, compared with cells stimulated with VEGF or FGF-1.
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Effect of PD173074 on the Anchorage-Independent Growth
of Human Pancreatic Cancer Cells
To determine the growth-inhibitory efficacy of PD173074
on anchorage-independent growth, we analyzed pancreatic
cancer cell lines in soft agar assays. Because of the dura-
tion and specific characteristics of this experimental setting,
we used 1.0 mM PD173074 in this experiment, which is a
concentration well below the IC50 concentration of pancre-
atic cancer cell lines. The well-differentiated human pancre-
atic cancer cell line Capan-1 did not grow in soft agar assays.
Figure 3. Dose-dependent and time-dependent effects of PD173074 on cell growth in different human pancreatic cancer cell lines. (A and B) Time-dependent
effect of PD173074 (10 M) on pancreatic cancer cell growth. (A) Cells were grown in complete cell medium for up to 96 hours in the presence of 10 M PD173074.
Cells were collected and counted with a hemocytometer. (B) Cells were cultured for 96 hours in complete cell medium in the presence of 10 M PD173074. Cell
viability was determined by MTT assay. (C and D) Dose-dependent effect of PD173074 on cell growth (48 hours). (C) Cells were grown in complete cell medium in
the presence of the indicated doses of PD173074 for 48 hours and analyzed as described in (A). In (D), cells were cultured and analyzed as described in (B), and
cell viability was determined by MTT assay. In (E), normal HUVECs and NHDFs were treated with PD173074, and cell viability was analyzed by MTT assay. Values
represent the mean ± SE of at least three independent experiments. *P < .05 indicates that the values for PD173074-treated cells were less statistically significant
than those for untreated cells. ns = not significant.
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In contrast, the growth of all four cell lines that grew in soft
agar was markedly inhibited, similar to that seen in mono-
layer cultures, although lower concentrations were needed
in anchorage-independent growth assays (Figure 4). In
summary, the growth-inhibitory effect of equal concentra-
tions of PD173074 was more pronounced in anchorage-
independent growth assays than in monolayer cultures,
where higher doses were needed for equal growth suppres-
sion (Figures 3 and 4).
Cell Cycle Arrest and Induction of Apoptosis after Treatment
with PD173074
To analyze how PD173074 modulates the cell growth of
pancreatic cancer cells in vitro, we analyzed whether
PD173074 inhibited cell cycle progression or caused apopto-
sis by FACS analysis using hypotonic PI and annexin V cell
stainings. Cell cycle progression was significantly inhibited
in all pancreatic cancer cell lines tested, but a clear differ-
ence was observed with regard to the potency of inhibition
(Table 1). AsPC-1 cells that expressed the highest levels of
FGF-RI protein reacted with the most pronounced G0/G1–
phase arrest (Table 1). Nevertheless, the HPAF-II cell line,
in which FGF-RI was not detectable, also displayed cell
cycle arrest, as seen as well for PANC-1 and MIA PaCa-2
cells (Table 1).
Apart from altering cell cycle progression, PD173047
therapy had a significant influence on apoptosis as it in-
creased the rate of apoptosis in pancreatic cancer cells
(Figure 5, A and B). Quantitative analysis of apoptotic rate
with annexin V staining showed that PD173074 dose-
dependently and time-dependently increased apoptosis
(Figure 5, A and B). This effect was first detectable at a dose
of 1.0 mM PD173074 in cells cultured for 48 hours. Similarly,
10 mM PD173074 resulted in an increase in apoptosis as
early as 24 hours after the onset of treatment. The potency of
induction was markedly different and more pronounced in
cells with higher FGF-RI levels. Noteworthy also, the FGF-
RI–negative cell line HAPF-II showed an increase in the
rate of apoptosis (Figure 5, A and B). The dose and time
dependencies of the effects of PD173074 on apoptosis over-
lapped with the corresponding effects of PD173074 on cell
count and cell viability (Figure 3).
Therapeutic Efficacy of PD173074 In Vivo
For in vivo studies, we used a highly metastatic murine
model for pancreatic cancer. One week after tumor induc-
tion, treatmentwas initiated, and 25mg/kg per dayPD173074
or an equal volume of solvent was injected intraperitoneally.
Treatment was continued for 10 weeks. Only moderate
side effects were seen in PD173074-treated animals, which
Table 1. Cell Cycle Phase Distribution of Pancreatic Cancer Cells Treated with PD173074.
AsPC-1 (%) Capan-1 (%) HPAF-II (%) MIA PaCa-2 (%) PANC-1 (%)
Control PD173074 Control PD173074 Control PD173074 Control PD173074 Control PD173074
48 hr G0/G1 39 59 42 59 46 55 41 58 39 67
S 43 32 37 29 35 29 48 31 34 18
G2/M 18 9 21 12 19 15 11 11 27 15
96 hr G0/G1 43 69 39 64 47 61 38 76 42 77
S 49 25 42 21 33 22 45 9 35 11
G2/M 8 6 19 15 20 17 17 15 23 12
Logarithmically growing pancreatic cancer cells were collected after 48 and 96 hours of treatment with 10 mM PD173074 and stained with PI, and DNA content was
subjected to flow cytometry analysis. The percentage of cells in each cell cycle phase was determined by the analysis of DNA content histograms using ModFit LT
software. Numbers in the G0/G1 phase that are presented in italics are statistically different from the corresponding control values (P < .05, Student’s t test). Values
from a representative experiment are presented, and similar results were obtained in at least two independent experiments.
Figure 4. Effect of PD173074 on anchorage-independent growth assays. (A)
Pancreatic cancer cells (103–104) were seeded on a bottom layer dependent
on individual cell growth rate. After 10 days of culture, the MTT reagent was
added as described in the Materials and Methods section. Colonies with > 20
cells were counted. Values represent the mean ± SE of at least three
independent experiments. *P < .05 indicates that values for PD173074-
treated cells were statistically significantly different from those for untreated
cells. (B) Representative culture of PANC-1 cells is shown. Untreated cells
(left well) compared to PD173074-treated cells (right well) are shown after the
MTT reagent has been added.
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had a lower weight in both groups compared to the sham-
treated animals.
PD173074 therapy resulted in significant tumor growth
suppression (Table 2). Overall growth-suppressive efficiency
was even more pronounced in the MIA PaCa-2 cell line
than in the HPAF-II cell line. Local tumor infiltration into peri-
pancreatic organs (e.g., stomach, liver, and spleen) was
lower in the treated groups. Tumor metastasis was de-
creased in MIA PaCa-2 xenograft tumors on PD173074
treatment (Table 2), and a clear trend in HPAF-II tumors
was seen, but this did not reach statistical significance in
HPAF-II animals. Furthermore, the production of ascites
in MIA PaCa-2 xenografted animals was reduced in the
treated group.
In an attempt to further translate our in vitro results, we
analyzed the apoptotic index in treated and untreated xeno-
graft tumors (Figure 6, A and B). The quantification of apop-
tosis in xenografts paralleled in vitro findings, as PD173074
significantly (P < .05) increased the rate of apoptosis in both
xenografted cell lines with a more pronounced effect on MIA
PaCa-2 xenograft tumors (13.1 ± 3.9% vs 3.7 ± 1.8%) but
also increased apoptosis in HPAF-II tumor xenografts (19.3 ±
6.2% vs 11.0 ± 4.1%).
Given the high potency of PD173074 for the simultaneous
blockade of FGF-RI and VEGF-RII, the MVD of xenograft
tumors was analyzed to test whether tumor-suppressive
effects were also due to blocked angiogenesis (Figure 6, C
and D). For specific identification, we stained tumor speci-
mens from both groups with an anti-mouse CD31 antibody—
a specific marker for blood vessel endothelium. MVD in
MIA PaCa-2 xenograft tumors was reduced by > 30% on
PD173074 treatment (41.9 ± 10.1 vs 63.4 ± 12.5), and a
similar reduction was seen in HPAF-II xenografts as well
(39.9 ± 12.8 vs 63.8 ± 13.2).
Discussion
Pancreatic cancer is a devastating disease with only a few
therapeutic options for the majority of patients, who have to
be treated palliatively. Even those patients who undergo
tumor resection often develop recurrent disease [42–44].
In a palliative therapeutic setting, radiation and chemo-
therapy offer—if at all—only marginal survival advantage
[43,45–47]. Therefore, new treatment strategies and com-
pounds are necessary to treat pancreatic cancer. Anti-
angiogenic therapy appears promising as it targets the
nutritional support of tumor cells by inhibiting blood vessel
formation [10,48,49]. Nevertheless, antiangiogenic therapy
is adjunctive only and is usually given together with addi-
tional cytotoxic compounds [49]. PD173074 is a novel small
molecule inhibitor, which blocks VEGF-RII and FGF-RI sig-
naling [27,28]. By its dual affinity, PD173074 simultaneously
exerts both the antiangiogenic and the antimitogenic ac-
tivities of these growth factors, thus abrogating two crucial
pathways in cancer growth and metastasis [41].
Because we have previously shown that mitogenic and
active VEGF-RII is expressed in human pancreatic cancer
cells in vitro and in vivo, we determined the expression of
FGF-RI in various human cell lines [41]. FGF-RI expression
was present in three of five pancreatic cancer cell lines, which
could be stimulated with recombinant FGF-1. This mitogenic
response induced by FGF-1 was completely revertible by
PD173074. Additionally, a strong antiproliferative effect was
observed in pancreatic cancer cells grown without further
stimulation by growth factors. This effect was both dose-
dependent and time-dependent in all cancer cell lines. Be-
cause higher doses of PD173074 inhibited the growth of all
cancer cell lines (even those that did not express FGF-RI), it
is likely that higher doses of PD173074 may also crossact
through nonspecific inhibition of other growth factor receptors
and tyrosine kinases. PD173074 demonstrated a selective
Table 2. Therapeutic Efficiency of PD173074 Treatment In Vivo Using a
Highly Metastatic Orthotopic Murine Model for Pancreatic Cancer.
Tumor Parameters MIA PaCa-2 HPAF-II
Sham PD173074 Sham PD173074
Tumor volume (cm3) 1.57 ± 0.3 0.46 ± 1.5* 1.72 ± 0.3 0.90 ± 0.3*
Metastatic score 2.20 ± 0.5 0.90 ± 0.3* 1.20 ± 0.4 1.00 ± 0.3
Ascites volume (ml) 2.10 ± 0.7 0.60 ± 0.2* 1.50 ± 0.6 0.55 ± 0.3
Animal weight (g) 27.6 ± 1.6 21.3 ± 0.9* 29.5 ± 1.9 22.6 ± 1.1*
*P < .05, unpaired t-test.
Figure 5. Dose and time dependencies of PD173074-induced apoptosis in different human pancreatic cancer cell lines. Cells were treated with PD173074 (10 M)
for the indicated time (A) or cultured for 48 hours in the presence of the indicated doses of PD173074 (B). Cells were trypsinized and stained with annexin V and PI.
Annexin V–positive and PI-negative cells were considered apoptotic. Values represent the mean ± SE of at least three independent experiments. *P < .05
indicates that for all cell lines studied, values for PD173074-treated cells were statistically significantly greater than those for untreated cells. ns = not significant.
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growth-inhibitory action toward HUVECs and normal human
fibroblasts when compared with a panel of pancreatic cancer
cells. In soft agar assays, a similar growth inhibition was
observed, but the drug doses required were lower than those
in monolayer cultures. Growth inhibition appeared to be
mediated by altered cell cycle progression in theG0/G1 phase
and by additional induction of apoptosis as determined by
flow cytometry.
Because PD1730474 appears to inhibit growth in vitro, we
tested the ability of this compound also in vivo using a highly
metastatic orthotopic murine model for pancreatic cancer. In
this study, we used a dose higher than that previously
described for antiangiogenic studies with nontransformed
endothelial cells [27]. In contrast, this study aimed to abro-
gate the mitogenesis of transformed cancer cells as well. In
general, this dose regimen was well tolerated. Tumor growth
in PD173074-treated animals was significantly reduced in
both MIA PaCa-2 and HPAF-II animals. In the highly meta-
static cell line MIA PaCa-2, there was also a lower incidence
of metastatic tumor spread and a lower volume of ascites
produced. A similar trend was seen in the dissemination
score of HPAF-II– tumor bearing animals, but this observa-
tion did not reach statistical significance due to the relatively
small sample size. The antitumor activity of PD173074 was
most likely due to the simultaneous targeting of several
cellular pathways affecting tumor cell proliferation, apoptosis,
and tumor angiogenesis. In as much as the number of newly
formed tumor blood vessels (MVD) may reflect the activity of
tumor neoangiogenesis, we determined the number of blood
vessels by staining them with endothelial-specific markers
and found that PD173074 led to a significant reduction in
tumor blood vessel formation. Clearly, reduction in the MVD
itself is not specific for the antiangiogenic activity of a chem-
ical compound because nonspecific tumor cell killing may
also cause a reduction in blood vessel formation. Similarly
treated animals showed a marked increase in apoptosis,
similar to the effect seen in vitro.
The current study is the first study to have used high doses
of PD173074 as a single compound and provides preclinical
evidence that PD173074 tailored cancer therapy toward the
simultaneous inhibition of angiogenesis, induction of apopto-
sis, and inhibition of tumor growth factor–mediated mito-
genesis. By therapeutic unification of these pathways, a
compound such as PD173074 may represent a new and
promising treatment option for patients suffering from pan-
creatic cancer.
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